GS
PMVP icon

GTS Securities’s PMV Pharmaceuticals PMVP Stock Holding History

GTS Securities’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,001
Closed -$12.4K – 1744
2026
Q1 		$12.4K Sell
10,001
-1
-0% -$1 ﹤0.01% 1464
2025
Q4 		$12.5K Buy
10,002
+1
+0% +$1 ﹤0.01% 1340
2025
Q3 		$14K Buy
+10,001
New +$13.8K ﹤0.01% 1391

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

GTS Securities's PMVP Position: Q2 2026 in Review

GTS Securities sold out of PMV Pharmaceuticals (PMVP) in Q2 2026, closing a stake of 10,001 shares — an estimated $12.4K sold.

GTS Securities first reported a position in PMVP in Q3 2025 and held it in 3 quarters. The position peaked at $14K in Q3 2025. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • GTS Securities reported no remaining PMV Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 10,001 PMV Pharmaceuticals shares in Q2 2026, an estimated $12.4K.
  • GTS Securities first reported a position in PMV Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • GTS Securities's PMV Pharmaceuticals position peaked at $14K in Q3 2025.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.